Mode
Text Size
Log in / Sign up

Regional lymphadenectomy improves survival in resectable gallbladder cancer: meta-analysisThorough lymph node removal improves survival for gallbladder cancer patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider regional lymphadenectomy (≥6 nodes) for resectable gallbladder cancer, but apply cautiously in T1b disease.

This meta-analysis of 27 studies evaluated the impact of regional lymphadenectomy (≥6 nodes, including retropancreatic and celiac stations) versus less extensive D1 clearance on survival in patients with resectable gallbladder cancer (T1b-T4). The primary outcome was overall survival (OS), with disease-free survival (DFS) as a secondary outcome.

The pooled analysis demonstrated a significant OS benefit for regional lymphadenectomy (HR 0.77; 95% CI 0.62-0.96). The benefit was more pronounced when at least 6 nodes were harvested (HR 0.68; 95% CI 0.57-0.81) and for D2 versus D1 dissection in T2/T3 tumors (HR 0.68; 95% CI 0.57-0.82). Thorough nodal removal also favored DFS (HR 0.63; 95% CI 0.48-0.83).

The authors acknowledge the retrospective nature of the included studies as a key limitation. No data on adverse events or follow-up duration were reported. The findings support a standardized surgical approach for resectable gallbladder cancer, but cautious application is advised for early-stage (T1b) disease due to limited evidence.

Gallbladder cancer is a serious illness that often returns after surgery. A new analysis looked at how much of the lymph nodes doctors remove during treatment. The goal is to find the best way to clear the cancer and help patients live longer. This review combined data from 27 different studies to see the real impact of surgical choices.

The main finding is clear. When surgeons remove at least six lymph nodes, including those in specific hard-to-reach areas, patients have a better chance of survival. The data shows a significant benefit for those who get this more thorough removal compared to less extensive surgery. This approach also helps patients stay free of the disease for longer periods.

The review focused on patients with resectable gallbladder cancer, which means the cancer can be surgically removed. The evidence comes from past records rather than a single new trial. While the results are promising, the nature of the data means doctors should apply these findings carefully, especially for patients with very early-stage disease.

What this means for you:
Removing more lymph nodes improves survival for patients with resectable gallbladder cancer.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
INTRODUCTION: The surgical management of gallbladder cancer (GBC) is complicated by aggressive lymphatic spread, leading to ongoing debate regarding the optimal extent of lymphadenectomy. This study aims to evaluate the stage-specific association between nodal harvest volume, anatomical templates, and survival outcomes. METHODS: A systematic review and meta-analysis of 27 studies (1999-2025) were conducted. Utilizing random-effects models and meta-regression, we evaluated Overall Survival (OS) and Disease-Free Survival (DFS) across pathological T-stages. RESULTS: Regional lymphadenectomy was associated with a significant overall survival benefit (HR 0.77, 95% CI: 0.62-0.96). Subgroup analysis and meta-regression (p = 0.768) suggested this association remains consistent across the T-stage spectrum (T1b-T4). Achieving a harvest of ≥6 nodes was identified as a critical quality benchmark (HR 0.68, 95% CI: 0.57-0.81). For T2 and T3 disease, D2 dissection (including retropancreatic and celiac stations) was associated with superior outcomes compared to D1 clearance (HR 0.68, 95% CI: 0.57-0.82). Secondary analysis of DFS similarly favored thorough nodal removal (HR 0.63, 95% CI: 0.48-0.83). CONCLUSION: Systematic lymphadenectomy of at least six nodes, incorporating the retropancreatic and celiac stations, is a critical quality metric associated with improved regional control and survival in resectable GBC. While these findings support a standardized approach, the retrospective nature of the evidence necessitates cautious application, particularly in early-stage (T1b) disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.